SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
SRI is developing a novel point-of-care tool for the early detection of devastating diseases.
SRI is seeking new treatments for tuberculosis, a global health crisis.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
SRI is developing a new therapeutic agent for influenza virus infections.
SRI is elucidating the mechanism of action of the drug of choice for the treatment of all known forms of human schistosomiasis.
SRI is enabling and improving metabolomics research with high-quality reference standards.
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
SRI is developing a method to enable rapid, large-scale response to a bioterrorism threat or an infectious disease epidemic.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
SRI sleep researchers are working to discover and develop new treatments for narcoleptic patients.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.